2025 Complete UK Guide to TIVA Protocols for Dogs — Top 7 Evidence-Based Intravenous Anesthetics (Propofol, Ketamine, Alfaxan, Dexmedetomidine, Butorphanol) — Veterinary-Endorsed Best Practice

Zoetis Propofol 1% holds its position as a go-to induction and TIVA agent in this 2025 British guide because of its predictable, rapid induction and rapid recoveries, making it ideal for short procedures and controlled intravenous infusions. Compared with alfaxalone products on this list it is often more familiar to UK clinicians and integrates well into multimodal protocols (for example ketofol or propofol with dexmedetomidine and butorphanol), though it typically requires adjunct analgesia and careful cardiovascular monitoring unlike the intrinsic analgesic-sparing effects of ketamine or dexmedetomidine.

Dechra Alfaxan Multidose is highlighted for its wide safety margin and cardiovascular stability in canine TIVA, offering veterinarians a UK-based, practice-oriented option with the convenience of a multidose vial and local technical support. Compared with propofol and Jurox alfaxalone, Dechra's product is positioned as a premium, well-documented alfaxalone formulation that may reduce hypotension risks seen with some propofol regimens, although it can be costlier than generic ketamine mixes.

Vetoquinol Ketamine 100mg/ml is noted for its strong utility as an analgesic and dissociative adjunct in TIVA protocols (notably ketofol), helping to preserve cardiovascular tone and reduce doses of primary hypnotics such as propofol or alfaxalone. In contrast to pure sedatives like dexmedetomidine or butorphanol, Vetoquinol’s ketamine is a cost-effective way to add analgesia and hemodynamic support, although clinicians must balance emergence phenomena and contraindications compared with the more easily reversible dexmedetomidine.

Zoetis Dexdomitor is selected for its potent alpha-2 sedation and analgesic-sparing effects that can markedly reduce propofol or alfaxalone infusion requirements in TIVA protocols, and its reversal with atipamezole adds an important safety and recovery-control advantage. Compared with opioid adjuncts like butorphanol or dissociatives like ketamine, Dexdomitor provides deeper sedation and better dose-sparing but requires vigilance for bradycardia and blood pressure changes, making product-specific dosing guidance from Zoetis valuable for UK clinicians.

Richter Pharma Butorphanol 10mg/ml is a cost-conscious, respiratory-sparing opioid option in this British guide, useful as a premed or infusion adjunct to smooth induction and recovery while modestly reducing hypnotic requirements. Compared with more potent analgesics like ketamine or dexmedetomidine, butorphanol offers a safer respiratory profile and predictable sedation that can be economically attractive in routine TIVA protocols, though it provides less profound analgesia than the dissociative or alpha-2 agents on the list.

Jurox Alfaxalone 10mg/ml is presented as a competitively priced alfaxalone alternative that delivers the neurosteroid advantages of alfaxalone for TIVA—rapid induction and generally smooth recoveries—while appealing to practices seeking budget-conscious options. Versus Dechra’s Alfaxan, Jurox may offer a lower-cost route to the same active drug class and is well-suited for multimodal regimens, although clinicians should compare vial formats and local support when choosing between alfaxalone brands.